S. Iannazzo, Maria Carla de Francesco, Barbara Coco, M. Brunetto, R. Tomić, D. Paolini, Giulio Palmieri, F. Bonino
{"title":"在意大利,使用干扰素alpha -2a治疗慢性hbeag -阴性肝炎的个性化治疗对预算的影响","authors":"S. Iannazzo, Maria Carla de Francesco, Barbara Coco, M. Brunetto, R. Tomić, D. Paolini, Giulio Palmieri, F. Bonino","doi":"10.1007/S40276-013-0015-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":187376,"journal":{"name":"PharmacoEconomics Italian Research Articles","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impatto sul budget di un trattamento personalizzato dell’epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana\",\"authors\":\"S. Iannazzo, Maria Carla de Francesco, Barbara Coco, M. Brunetto, R. Tomić, D. Paolini, Giulio Palmieri, F. Bonino\",\"doi\":\"10.1007/S40276-013-0015-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":187376,\"journal\":{\"name\":\"PharmacoEconomics Italian Research Articles\",\"volume\":\"7 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Italian Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/S40276-013-0015-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Italian Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/S40276-013-0015-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Impatto sul budget di un trattamento personalizzato dell’epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana